<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02256319</url>
  </required_header>
  <id_info>
    <org_study_id>DEXPROPAR</org_study_id>
    <nct_id>NCT02256319</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine vs Propofol on the Recordings of Deep Brain Activity Measured Through Implanted Stimulators</brief_title>
  <acronym>DEXPROPAR</acronym>
  <official_title>Effects of Dexmedetomidine vs Propofol on the Recordings of Deep Brain Activity (Local Field Potentials) Measured Through Implanted Stimulators</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinica Universidad de Navarra, Universidad de Navarra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinica Universidad de Navarra, Universidad de Navarra</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial has been designed to study and compare changes in deep brain activity
      (field potentials) in Parkinson's disease (PD) patients while awake, and during sedation with
      dexmedetomidine or propofol. The recording is made through a deep brain stimulation (DBS)
      electrode implanted for PD management.

      The investigators hypothesize that dexmedetomidine produces fewer changes as compared to
      propofol, and that those changes are consistent and recognizable when compared to activity in
      patients not exposed to any sedation. Typification of those changes would in the future allow
      for patients to undergo this surgery comfortably while not compromising the quality of the
      recording and of the final clinical outcome. The principal variable analyzed is the signal's
      power in each of the frequency bands, absolute and relative. The analysis will include usual
      clinical methods such as rapid Fourier transform (FFT) and window fast Fourier transform
      (WFFT), wavelet analysis, Gabor, and coherence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparative clinical trial, non blinded, controlled and sequential, evaluating the effects of
      propofol and dexmedetomidine in the basal ganglia of PD patients through a DBS electrode.

      It is a phase IV clinical trial evaluating the effects of a drug outside the approved.

      The study takes part in three phases:

        1. DBS placement under sedation with dexmedetomidine at 0.2 μg/kg/h. This will be called
           &quot;dexmedetomidine record&quot;.

        2. Four days later and with no sedation, a recording will be registered in one of the
           specialized electrically isolated rooms at the Neurophysiology Department. This will be
           dubbed &quot;basal recording&quot;. The equipment used is also the standard one used for routine
           postoperative recordings.

        3. 5 days after the initial surgery, and following the protocol in place for these
           procedures, the tunnelization and battery placement will take place. This is done under
           general anaesthesia. During anaesthetic induction, the patient is exposed to incremental
           doses of propofol. Different plasmatic concentrations will be targeted using the
           mathematical model in the target controlled infusion (TCI) pump. These recordings will
           be called &quot;propofol at a 0.5, 1, 1.5, 2, 2.5 μg/mL&quot;.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Signal power of the local field potentials.</measure>
    <time_frame>5 minutes for each record</time_frame>
    <description>Signal power separated in bandwidth (theta, slow beta, fast beta, gamma, high frequency); absolute and relative. The comparison will be made between the different measurements: dexmedetomidine, basal and propofol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>UPDRS-III score</measure>
    <time_frame>2 minutes for each score</time_frame>
    <description>Changes in UPDRS-III score with dexmedetomidine and propofol</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine recording</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recording registered through the deep brain stimulation electrodes with dexmedetomidine at 0.2 μg/kg/h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol recording</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Recording registered through the deep brain stimulation electrodes with propofol at plasmatic levels of 0.5, 1, 1.5, 2, 2.5 μg/mL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Basal recording</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Recording registered through the deep brain stimulation electrodes with no sedation .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Patients will receive a loading dose of 1 µg/kg in 10 min before starting the surgery. The maintenance dose will be 0.2-1 µg/kg/h for a Ramsey Sedation Score of 3-4 during the surgery´s preparation. It will be reduced to 0.2 µg/kg/h 15 min before starting the microelectrode recording for a Ramsey Sedation Score of 2. After the placement of the deep brain stimulator we will record the local field potentials activity. In addition, the subscales of rigidity, tremor and bradykinesia of the Unified Parkinson's Disease Rating Scale (UPDRS-III) score will be evaluated. Once the deep brain stimulator recording and neurologic exploration will be over patients will receive a maintenance dose 0.2-1 µg/kg/h until the end of the surgery. It will be stopped to transfer the patient to the ICU.</description>
    <arm_group_label>Dexmedetomidine recording</arm_group_label>
    <other_name>(S)-4-[1-(2,3-Dimethylphenyl)ethyl]-3H-imidazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>The target doses are 0.5, 1, 1.5, 2 and 2.5 µg/kg. For its administration we will use the TCI (target controlled infusion) system. After programming each dose we will wait until the plasma and brain concentration of propofol are stabilized in this target and then we will record the local field potentials activity through the DBS. In addition, the subscales of rigidity, tremor and bradykinesia of the UPDRS-III score will be evaluated.</description>
    <arm_group_label>Propofol recording</arm_group_label>
    <other_name>2,6-diisopropylphenol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Capacity to understand, consent and commit for the three phases of the study.

          -  Older than 18 years old.

          -  The patient is scheduled for DBS electrode placement for PD treatment by his
             neurologist.

        Exclusion Criteria:

          -  Allergy or hypersensibility to dexmedetomidine or propofol

          -  Cardiac blockade (types 2 and 3) without an implanted pacemaker

          -  Low blood pressure (mean &lt; 60 mmHg) or symptoms of low cardiac output.

          -  Severe cerebrovascular disease.

          -  Pregnancy or nursing mothers.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martínez S Antonio, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Staff of the deparment of Anestesiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Navarra Clinic</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Krack P, Batir A, Van Blercom N, Chabardes S, Fraix V, Ardouin C, Koudsie A, Limousin PD, Benazzouz A, LeBas JF, Benabid AL, Pollak P. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med. 2003 Nov 13;349(20):1925-34.</citation>
    <PMID>14614167</PMID>
  </reference>
  <reference>
    <citation>Hamani C, Richter E, Schwalb JM, Lozano AM. Bilateral subthalamic nucleus stimulation for Parkinson's disease: a systematic review of the clinical literature. Neurosurgery. 2005 Jun;56(6):1313-21; discussion 1321-4. Review.</citation>
    <PMID>15918948</PMID>
  </reference>
  <reference>
    <citation>Poon CC, Irwin MG. Anaesthesia for deep brain stimulation and in patients with implanted neurostimulator devices. Br J Anaesth. 2009 Aug;103(2):152-65. doi: 10.1093/bja/aep179. Epub 2009 Jun 25. Review.</citation>
    <PMID>19556271</PMID>
  </reference>
  <reference>
    <citation>Sassi M, Zekaj E, Grotta A, Pollini A, Pellanda A, Borroni M, Pacchetti C, Menghetti C, Porta M, Servello D. Safety in the use of dexmedetomidine (precedex) for deep brain stimulation surgery: our experience in 23 randomized patients. Neuromodulation. 2013 Sep-Oct;16(5):401-6; discussion 406. doi: 10.1111/j.1525-1403.2012.00483.x. Epub 2012 Jul 10.</citation>
    <PMID>22780449</PMID>
  </reference>
  <reference>
    <citation>Rozet I, Muangman S, Vavilala MS, Lee LA, Souter MJ, Domino KJ, Slimp JC, Goodkin R, Lam AM. Clinical experience with dexmedetomidine for implantation of deep brain stimulators in Parkinson's disease. Anesth Analg. 2006 Nov;103(5):1224-8.</citation>
    <PMID>17056959</PMID>
  </reference>
  <reference>
    <citation>Reck C, Florin E, Wojtecki L, Krause H, Groiss S, Voges J, Maarouf M, Sturm V, Schnitzler A, Timmermann L. Characterisation of tremor-associated local field potentials in the subthalamic nucleus in Parkinson's disease. Eur J Neurosci. 2009 Feb;29(3):599-612. doi: 10.1111/j.1460-9568.2008.06597.x. Epub 2009 Jan 28.</citation>
    <PMID>19187268</PMID>
  </reference>
  <reference>
    <citation>Rodriguez-Oroz MC, López-Azcárate J, Garcia-Garcia D, Alegre M, Toledo J, Valencia M, Guridi J, Artieda J, Obeso JA. Involvement of the subthalamic nucleus in impulse control disorders associated with Parkinson's disease. Brain. 2011 Jan;134(Pt 1):36-49. doi: 10.1093/brain/awq301. Epub 2010 Nov 8.</citation>
    <PMID>21059746</PMID>
  </reference>
  <reference>
    <citation>Urrestarazu E, Iriarte J, Alegre M, Clavero P, Rodríguez-Oroz MC, Guridi J, Obeso JA, Artieda J. Beta activity in the subthalamic nucleus during sleep in patients with Parkinson's disease. Mov Disord. 2009 Jan 30;24(2):254-60. doi: 10.1002/mds.22351.</citation>
    <PMID>18951542</PMID>
  </reference>
  <results_reference>
    <citation>Rodriguez-Oroz MC, Obeso JA, Lang AE, Houeto JL, Pollak P, Rehncrona S, Kulisevsky J, Albanese A, Volkmann J, Hariz MI, Quinn NP, Speelman JD, Guridi J, Zamarbide I, Gironell A, Molet J, Pascual-Sedano B, Pidoux B, Bonnet AM, Agid Y, Xie J, Benabid AL, Lozano AM, Saint-Cyr J, Romito L, Contarino MF, Scerrati M, Fraix V, Van Blercom N. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain. 2005 Oct;128(Pt 10):2240-9. Epub 2005 Jun 23.</citation>
    <PMID>15975946</PMID>
  </results_reference>
  <results_reference>
    <citation>Venkatraghavan L, Manninen P. Anesthesia for deep brain stimulation. Curr Opin Anaesthesiol. 2011 Oct;24(5):495-9. doi: 10.1097/ACO.0b013e32834a894c. Review.</citation>
    <PMID>21772140</PMID>
  </results_reference>
  <results_reference>
    <citation>Venkatraghavan L, Luciano M, Manninen P. Review article: anesthetic management of patients undergoing deep brain stimulator insertion. Anesth Analg. 2010 Apr 1;110(4):1138-45. doi: 10.1213/ANE.0b013e3181d2a782. Epub 2010 Feb 8. Review.</citation>
    <PMID>20142347</PMID>
  </results_reference>
  <results_reference>
    <citation>Raz A, Eimerl D, Zaidel A, Bergman H, Israel Z. Propofol decreases neuronal population spiking activity in the subthalamic nucleus of Parkinsonian patients. Anesth Analg. 2010 Nov;111(5):1285-9. doi: 10.1213/ANE.0b013e3181f565f2. Epub 2010 Sep 14.</citation>
    <PMID>20841416</PMID>
  </results_reference>
  <results_reference>
    <citation>Steigerwald F, Hinz L, Pinsker MO, Herzog J, Stiller RU, Kopper F, Mehdorn HM, Deuschl G, Volkmann J. Effect of propofol anesthesia on pallidal neuronal discharges in generalized dystonia. Neurosci Lett. 2005 Oct 7;386(3):156-9.</citation>
    <PMID>16024174</PMID>
  </results_reference>
  <results_reference>
    <citation>Rozet I. Anesthesia for functional neurosurgery: the role of dexmedetomidine. Curr Opin Anaesthesiol. 2008 Oct;21(5):537-43. doi: 10.1097/ACO.0b013e32830edafd. Review.</citation>
    <PMID>18784476</PMID>
  </results_reference>
  <results_reference>
    <citation>Elias WJ, Durieux ME, Huss D, Frysinger RC. Dexmedetomidine and arousal affect subthalamic neurons. Mov Disord. 2008 Jul 15;23(9):1317-20. doi: 10.1002/mds.22080. Erratum in: Mov Disord. 2008 Aug 15;23(11):1638.</citation>
    <PMID>18442130</PMID>
  </results_reference>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2014</study_first_submitted>
  <study_first_submitted_qc>October 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2014</study_first_posted>
  <last_update_submitted>December 17, 2015</last_update_submitted>
  <last_update_submitted_qc>December 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Deep brain stimulation</keyword>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Propofol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

